TearLab released a statement recognizing Shire on its recent FDA approval of Xiidra (lifitegrast ophthalmic solution) 5% for the treatment of signs and symptoms of dry eye disease (DED).
“We would like to extend our sincere congratulations to Shire on securing FDA approval for Xiidra in the treatment of signs and symptoms of DED. As the first new DED prescription therapy approved in the U.S. in the past 13 years, this is an important milestone for the ophthalmic industry and the millions of DED patients in the U.S. We believe Shire’s approval will improve awareness and lead to increased participation in the DED space,” Seph Jensen, TearLab's Chief Executive Officer, said in the news release.
Dr. Edward Holland, MD, Professor of Clinical Ophthalmology, University of Cincinnati added, “FDA approval of Xiidra is an exciting development for eye care professionals and dry eye sufferers alike. As with any new drug, properly identifying patients most likely to benefit from treatment will be critical. TearLab’s osmolarity test represents an important diagnostic tool to help identify DED patients and enable physicians to make more informed treatment decisions.”